- Home
- ANTA vs IMMP Comparison
ANTA vs IMMP Comparison
Compare ANTA & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTA
- IMMP
- Stock Information
- Founded
- ANTA 2022
- IMMP 1987
- Country
- ANTA Singapore
- IMMP Australia
- Employees
- ANTA N/A
- IMMP N/A
- Industry
- ANTA Investment Bankers/Brokers/Service
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- ANTA Finance
- IMMP Health Care
- Exchange
- ANTA Nasdaq
- IMMP Nasdaq
- Market Cap
- ANTA 256.6M
- IMMP 244.5M
- IPO Year
- ANTA 2025
- IMMP N/A
- Fundamental
- Price
- ANTA $11.37
- IMMP $1.65
- Analyst Decision
- ANTA Strong Buy
- IMMP Buy
- Analyst Count
- ANTA 2
- IMMP 1
- Target Price
- ANTA $19.25
- IMMP $7.00
- AVG Volume (30 Days)
- ANTA 68.5K
- IMMP 87.0K
- Earning Date
- ANTA 06-17-2025
- IMMP 02-27-2025
- Dividend Yield
- ANTA N/A
- IMMP N/A
- EPS Growth
- ANTA N/A
- IMMP N/A
- EPS
- ANTA 0.29
- IMMP N/A
- Revenue
- ANTA $51,404,954.00
- IMMP $3,019,249.00
- Revenue This Year
- ANTA N/A
- IMMP $50.37
- Revenue Next Year
- ANTA N/A
- IMMP N/A
- P/E Ratio
- ANTA $39.05
- IMMP N/A
- Revenue Growth
- ANTA 320.96
- IMMP 24.11
- 52 Week Low
- ANTA $10.19
- IMMP $1.32
- 52 Week High
- ANTA $27.72
- IMMP $2.72
- Technical
- Relative Strength Index (RSI)
- ANTA N/A
- IMMP 46.73
- Support Level
- ANTA N/A
- IMMP $1.64
- Resistance Level
- ANTA N/A
- IMMP $1.74
- Average True Range (ATR)
- ANTA 0.00
- IMMP 0.06
- MACD
- ANTA 0.00
- IMMP 0.01
- Stochastic Oscillator
- ANTA 0.00
- IMMP 66.67
About ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to the digital asset industry. It is a provider of supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. It has developed a technology platform, Antalpha Prime, which enables customers to apply for and manage their digital asset loans while allowing to closely monitor collateral positions.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.